101
|
Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B, Ricotta R, Gasparro D, Sabbatini R, Ceresoli GL, Mosca A, Santini D, Caserta C, Cavanna L, Massari F, Sava T, Boni C, Verzoni E, Cartenì G, Hamzaj A. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol 2015. [PMID: 26216384 DOI: 10.1093/annonc/mdv315] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND First-line sunitinib is recommended in metastatic renal cell carcinoma (mRCC), but it is frequently associated with relevant toxicities and subsequent dose reductions. Alternative schedules, such as 2-week-on treatment and 1-week-off (2/1 schedule), might improve tolerability. We evaluated the safety and outcomes of this schedule in a large multicenter analysis. PATIENTS AND METHODS Retrospective, multicenter analysis of mRCC patients treated with first-line sunitinib on a 2/1 schedule. Data of 249 patients were reviewed: 208 cases who started sunitinib on the 4/2 schedule (full dosage: 188/208, 90.4%) and thereafter switched to the 2/1 schedule for toxicity (group 4/2 → 2/1) and 41 patients who started first-line sunitinib with the 2/1 schedule because of suboptimal clinical conditions (group 2/1). A total of 211 consecutive patients treated with the 4/2 schedule in another institution served as external controls. Safety was the primary end point. Treatment duration (TD), progression-free survival (PFS) and overall survival (OS) were also analyzed. RESULTS In group 4/2 → 2/1, the overall incidence of grade ≥ 3 toxicities was significantly reduced (from 45.7% to 8.2%, P < 0.001) after the switch to 2/1 schedule. This advantage was maintained also in the 106/188 cases (56.4%) who maintained the full dosage. Fatigue, hypertension, hand-foot syndrome and thrombocytopenia were less frequent. The incidence of grade ≥ 3 adverse events in the negatively selected group 2/1 (only 73.2% starting at full dose) was 26.8%, similar to what observed in the external control group (29.4%). Median TD was 28.2 months in the 4/2 → 2/1 group (total time spent with both schedules), 7.8 months in the 2/1 group and 9.7 months in external controls. Median PFS was 30.2, 10.4 and 9.7 months, respectively. Median OS was not reached, 23.2 and 27.8 months, respectively. CONCLUSIONS mRCC patients who moved to a modified 2/1 schedule of sunitinib experience an improved safety profile compared with that observed during the initial 4/2 schedule.
Collapse
|
102
|
Rulli E, Marabese M, Torri V, Farina G, Veronese S, Bettini A, Longo F, Moscetti L, Ganzinelli M, Lauricella C, Copreni E, Labianca R, Martelli O, Marsoni S, Broggini M, Garassino MC. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. Ann Oncol 2015. [PMID: 26209642 DOI: 10.1093/annonc/mdv318] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND The prognostic and predictive role of KRAS mutations in advanced nonsmall-cell lung cancer (NSCLC) is still unclear. TAILOR prospectively assessed the prognostic and predictive value of KRAS mutations in NSCLC patients treated with erlotinib or docetaxel in second line. PATIENTS AND METHODS NSCLC patients from 52 Italian hospitals were genotyped for KRAS and EGFR mutational status in two independent laboratories. Wild-type EGFR patients (N = 218) received first-line platinum-based chemotherapy and were randomly allocated at progression to erlotinib or docetaxel. Overall survival (OS) according to KRAS mutational status was the primary end point. RESULTS KRAS mutations were present in 23% of TAILOR randomized cases. The presence of a KRAS mutation did not adversely affect progression-free (PFS) or overall (OS) survival [hazard ratio (HR) PFS = 1.01, 95% confidence interval (CI) 0.71-1.41, P = 0.977; OS = 1.24, 95% CI 0.87-1.77, P = 0.233], nor influenced treatment outcome (test for interaction: OS P = 0.965; PFS P = 0.417). Patients randomized to docetaxel treatment experienced longer survival independently from the KRAS mutational status of their tumors (HR: mutated KRAS 0.81, 95% CI 0.45-1.47; wild-type KRAS 0.79, 95% CI 0.57-1.10). CONCLUSION In TAILOR, KRAS was neither prognostic nor predictive of benefit for either docetaxel or erlotinib. Docetaxel remains superior independently from KRAS status for second-line treatment in EGFR wild-type advanced NSCLC patients. CLINICAL TRIAL REGISTRATION NCT00637910.
Collapse
|
103
|
Pannone G, Santoro A, Feola A, Bufo P, Papagerakis P, Lo Muzio L, Staibano S, Ionna F, Longo F, Franco R, Aquino G, Contaldo M, De Maria S, Serpico R, De Rosa A, Rubini C, Papagerakis S, Giovane A, Tombolini V, Giordano A, Caraglia M, Di Domenico M. The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage. Curr Cancer Drug Targets 2015; 14:115-27. [PMID: 24274398 DOI: 10.2174/1568009613666131126115012] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2013] [Revised: 08/29/2013] [Accepted: 08/29/2013] [Indexed: 11/22/2022]
Abstract
BACKGROUND The prognosis of the oral squamous cell carcinoma (OSCC) patients remains very poor, mainly due to their high propensity to invade and metastasize. E-cadherin reduced expression occurs in the primary step of oral tumour progression and gene methylation is a mode by which the expression of this protein is regulated in cancers. In this perspective, we investigated E-cadherin gene (CDH1) promoter methylation status in OSCC and its correlation with Ecadherin protein expression, clinicopathological characteristics and patient outcome. METHODS Histologically proven OSCC and paired normal mucosa were analyzed for CDH1 promoter methylation status and E-cadherin protein expression by methylation-specific polymerase chain reaction and immunohistochemistry. Colocalization of E-cadherin with epidermal growth factor (EGF) receptor (EGFR) was evidenced by confocal microscopy and by immunoprecipitation analyses. RESULTS This study indicated E-cadherin protein down-regulation in OSCC associated with protein delocalization from membrane to cytoplasm. Low E-cadherin expression correlated to aggressive, poorly differentiated, high grade carcinomas and low patient survival. Moreover, protein down-regulation appeared to be due to E-cadherin mRNA downregulation and CDH1 promoter hypermethylation. In an in vitro model of OSCC the treatment with EGF caused internalization and co-localization of E-cadherin with EGFR and the addition of demethylating agents increased E-cadherin expression. CONCLUSION Low E-Cadherin expression is a negative prognostic factor of OSCC and is likely due to the hypermethylation of CDH1 promoter. The delocalization of E-cadherin from membrane to cytoplasm could be also due to the increased expression of EGFR in OSCC and the consequent increase of E-cadherin co-internalization with EGFR.
Collapse
|
104
|
Acero F, Ackermann M, Ajello M, Albert A, Atwood WB, Axelsson M, Baldini L, Ballet J, Barbiellini G, Bastieri D, Belfiore A, Bellazzini R, Bissaldi E, Blandford RD, Bloom ED, Bogart JR, Bonino R, Bottacini E, Bregeon J, Britto RJ, Bruel P, Buehler R, Burnett TH, Buson S, Caliandro GA, Cameron RA, Caputo R, Caragiulo M, Caraveo PA, Casandjian JM, Cavazzuti E, Charles E, Chaves RCG, Chekhtman A, Cheung CC, Chiang J, Chiaro G, Ciprini S, Claus R, Tanugi JC, Cominsky LR, Conrad J, Cutini S, D’Ammando F, Angelis AD, DeKlotz M, Palma FD, Desiante R, Digel SW, Venere LD, Drell PS, Dubois R, Dumora D, Favuzzi C, Fegan SJ, Ferrara EC, Finke J, Franckowiak A, Fukazawa Y, Funk S, Fusco P, Gargano F, Gasparrini D, Giebels B, Giglietto N, Giommi P, Giordano F, Giroletti M, Glanzman T, Godfrey G, Grenier IA, Grondin MH, Grove JE, Guillemot L, Guiriec S, Hadasch D, Harding AK, Hays E, Hewitt JW, Hill AB, Horan D, Iafrate G, Jogler T, Jóhannesson G, Johnson RP, Johnson AS, Johnson TJ, Johnson WN, Kamae T, Kataoka J, Katsuta J, Kuss M, Mura GL, Landriu D, Larsson S, Latronico L, Goumard ML, Li J, Li L, Longo F, Loparco F, Lott B, Lovellette MN, Lubrano P, Madejski GM, Massaro F, Mayer M, Mazziotta MN, McEnery JE, Michelson PF, Mirabal N, Mizuno T, Moiseev AA, Mongelli M, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Nuss E, Ohno M, Ohsugi T, Omodei N, Orienti M, Orlando E, Ormes JF, Paneque D, Panetta JH, Perkins JS, Rollins MP, Piron F, Pivato G, Porter TA, Racusin JL, Rando R, Razzano M, Razzaque S, Reimer A, Reimer O, Reposeur T, Rochester LS, Romani RW, Salvetti D, Conde MS, Parkinson PMS, Schulz A, Siskind EJ, Smith DA, Spada F, Spandre G, Spinelli P, Stephens TE, Strong AW, Suson DJ, Takahashi H, Takahashi T, Tanaka Y, Thayer JG, Thayer JB, Thompson DJ, Tibaldo L, Tibolla O, Torres DF, Torresi E, Tosti G, Troja E, Klaveren BV, Vianello G, Winer BL, Wood KS, Wood M, Zimmer S. FERMI
LARGE AREA TELESCOPE THIRD SOURCE CATALOG. ACTA ACUST UNITED AC 2015. [DOI: 10.1088/0067-0049/218/2/23] [Citation(s) in RCA: 1146] [Impact Index Per Article: 127.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
105
|
Gholami S, Meigooni AS, Nedaie H, Longo F, Ay M. SU-E-T-461: Impact of the Radiation Sensitivity of Tumor and Geometric Design of the GRID Block On the Clinical Response of Grid Therapy. Med Phys 2015. [DOI: 10.1118/1.4924823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
106
|
Aleksić J, Ansoldi S, Antonelli LA, Antoranz P, Babic A, Bangale P, Barrio JA, González JB, Bednarek W, Bernardini E, Biasuzzi B, Biland A, Blanch O, Bonnefoy S, Bonnoli G, Borracci F, Bretz T, Carmona E, Carosi A, Colin P, Colombo E, Contreras JL, Cortina J, Covino S, Da Vela P, Dazzi F, De Angelis A, De Caneva G, De Lotto B, Wilhelmi EDO, Mendez CD, Prester DD, Dorner D, Doro M, Einecke S, Eisenacher D, Elsaesser D, Fonseca MV, Font L, Frantzen K, Fruck C, Galindo D, López RJG, Garczarczyk M, Terrats DG, Gaug M, Godinović N, Muñoz AG, Gozzini SR, Hadasch D, Hanabata Y, Hayashida M, Herrera J, Hildebrand D, Hose J, Hrupec D, Idec W, Kadenius V, Kellermann H, Kodani K, Konno Y, Krause J, Kubo H, Kushida J, La Barbera A, Lelas D, Lewandowska N, Lindfors E, Lombardi S, Longo F, López M, López-Coto R, López-Oramas A, Lorenz E, Lozano I, Makariev M, Mallot K, Maneva G, Mankuzhiyil N, Mannheim K, Maraschi L, Marcote B, Mariotti M, Martínez M, Mazin D, Menzel U, Miranda JM, Mirzoyan R, Moralejo A, Munar-Adrover P, Nakajima D, Niedzwiecki A, Nilsson K, Nishijima K, Noda K, Orito R, Overkemping A, Paiano S, Palatiello M, Paneque D, Paoletti R, Paredes JM, Paredes-Fortuny X, Persic M, Poutanen J, Moroni PGP, Prandini E, Puljak I, Reinthal R, Rhode W, Ribó M, Rico J, Garcia JR, Rügamer S, Saito T, Saito K, Satalecka K, Scalzotto V, Scapin V, Schultz C, Schweizer T, Shore SN, Sillanpää A, Sitarek J, Snidaric I, Sobczynska D, Spanier F, Stamatescu V, Stamerra A, Steinbring T, Storz J, Strzys M, Takalo L, Takami H, Tavecchio F, Temnikov P, Terzić T, Tescaro D, Teshima M, Thaele J, Tibolla O, Torres DF, Toyama T, Treves A, Uellenbeck M, Vogler P, Zanin R, Kadler M, Schulz R, Ros E, Bach U, Krauß F, Wilms J. Black hole lightning due to particle acceleration at subhorizon scales. Science 2014; 346:1080-4. [DOI: 10.1126/science.1256183] [Citation(s) in RCA: 100] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
107
|
Ackermann M, Albert A, Atwood WB, Baldini L, Ballet J, Barbiellini G, Bastieri D, Bellazzini R, Bissaldi E, Blandford RD, Bloom ED, Bottacini E, Brandt TJ, Bregeon J, Bruel P, Buehler R, Buson S, Caliandro GA, Cameron RA, Caragiulo M, Caraveo PA, Cavazzuti E, Cecchi C, Charles E, Chekhtman A, Chiang J, Chiaro G, Ciprini S, Claus R, Cohen-Tanugi J, Conrad J, Cutini S, D'Ammando F, de Angelis A, de Palma F, Dermer CD, Digel SW, Venere LD, do Couto e Silva E, Drell PS, Favuzzi C, Ferrara EC, Focke WB, Franckowiak A, Fukazawa Y, Funk S, Fusco P, Gargano F, Gasparrini D, Germani S, Giglietto N, Giordano F, Giroletti M, Godfrey G, Gomez-Vargas GA, Grenier IA, Guiriec S, Hadasch D, Harding AK, Hays E, Hewitt JW, Hou X, Jogler T, Jóhannesson G, Johnson AS, Johnson WN, Kamae T, Kataoka J, Knödlseder J, Kocevski D, Kuss M, Larsson S, Latronico L, Longo F, Loparco F, Lovellette MN, Lubrano P, Malyshev D, Manfreda A, Massaro F, Mayer M, Mazziotta MN, McEnery JE, Michelson PF, Mitthumsiri W, Mizuno T, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Nemmen R, Nuss E, Ohsugi T, Omodei N, Orienti M, Orlando E, Ormes JF, Paneque D, Panetta JH, Perkins JS, Pesce-Rollins M, Petrosian V, Piron F, Pivato G, Rainò S, Rando R, Razzano M, Razzaque S, Reimer A, Reimer O, Sánchez-Conde M, Schaal M, Schulz A, Sgrò C, Siskind EJ, Spandre G, Spinelli P, Stawarz Ł, Strong AW, Suson DJ, Tahara M, Takahashi H, Thayer JB, Tibaldo L, Tinivella M, Torres DF, Tosti G, Troja E, Uchiyama Y, Vianello G, Werner M, Winer BL, Wood KS, Wood M, Zaharijas G. THE SPECTRUM AND MORPHOLOGY OF THEFERMIBUBBLES. ACTA ACUST UNITED AC 2014. [DOI: 10.1088/0004-637x/793/1/64] [Citation(s) in RCA: 207] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
108
|
Olmedo M, Mezquita L, Earl J, Benito A, Santon A, Longo F, Vallejo C, MuÑoz G, Gorospe L, Soria A, Gordoa TA, Grande E, Roberts E, Gomez A, Cortez P, Alcalde R, Muñoz J, Cortés A, Carrato A, Garrido P. Monitoring Circulating Tumor Cells (Ctc) in Lung Cancer: Preliminary Results. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu326.81] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
109
|
Guida F, Santoni M, De Giorgi U, De Tursi M, Procopio G, Pignata S, Galli L, Di Lorenzo G, Badalamenti G, Felici A, Marchetti P, Iacovelli R, Longo F, Maruzzo M, Massari F, Suarez C, Aieta M, Cascinu S, Milella M, Santini D. Poor Risk Metastatic Renal Cell Carcinoma (Mrcc) Patients are not a Homogeneous Group: a New Stratificating Model in the Era of Targeted Therapy. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu337.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
110
|
Longo F, Guida A, Aversa C, Pavone E, Di Costanzo G, Ramaglia L, Ionna F. Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literature. Int J Dent 2014; 2014:298945. [PMID: 25013411 PMCID: PMC4071853 DOI: 10.1155/2014/298945] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2014] [Accepted: 05/19/2014] [Indexed: 11/18/2022] Open
Abstract
Bisphosphonates (BPs) are a class of synthetic drugs commonly used to treat bone metastasis and various bone diseases that cause osseous fragility (such as osteoporosis). Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a common complication in patients who received BPs, especially intravenously. Recently, osteonecrosis of the jaw (ONJ) caused by chemotherapeutic not belonging to BPs drug class has been reported. For this reason, it has been proposed recently to rename BRONJ in antiresorptive agents related osteonecrosis of the jaw (ARONJ), to include a wider spectrum of drugs that may cause osteonecrosis of the jaw. The most debated topic about ARONJ/BRONJ is therapy. The most adequate procedure is far from being standardized and prevention seems to play a pivotal role. In our study, we considered 72 patients with BRONJ with nonsurgical therapy, surgical therapy, and surgical therapy with platelet rich plasma (PRP) gel to evaluate its therapeutic effect in promoting ONJ wounds healing. Good results showed by PRP in improving wound healing give away to case-control randomized studies that could give definitive evidence of its effectiveness.
Collapse
|
111
|
Ackermann M, Ajello M, Albert A, Allafort A, Baldini L, Barbiellini G, Bastieri D, Bechtol K, Bellazzini R, Blandford RD, Bloom ED, Bonamente E, Bottacini E, Bouvier A, Brandt TJ, Brigida M, Bruel P, Buehler R, Buson S, Caliandro GA, Cameron RA, Caraveo PA, Cecchi C, Charles E, Chaves RCG, Chekhtman A, Chiang J, Chiaro G, Ciprini S, Claus R, Cohen-Tanugi J, Conrad J, Cutini S, Dalton M, D'Ammando F, de Angelis A, de Palma F, Dermer CD, Digel SW, Di Venere L, do Couto e Silva E, Drell PS, Drlica-Wagner A, Favuzzi C, Fegan SJ, Ferrara EC, Focke WB, Franckowiak A, Fukazawa Y, Funk S, Fusco P, Gargano F, Gasparrini D, Germani S, Giglietto N, Giordano F, Giroletti M, Glanzman T, Godfrey G, Gomez-Vargas GA, Grenier IA, Grove JE, Guiriec S, Gustafsson M, Hadasch D, Hanabata Y, Harding AK, Hayashida M, Hayashi K, Hewitt JW, Horan D, Hou X, Hughes RE, Inoue Y, Jackson MS, Jogler T, Jóhannesson G, Johnson AS, Kamae T, Kawano T, Knödlseder J, Kuss M, Lande J, Larsson S, Latronico L, Longo F, Loparco F, Lovellette MN, Lubrano P, Mayer M, Mazziotta MN, McEnery JE, Mehault J, Michelson PF, Mitthumsiri W, Mizuno T, Moiseev AA, Monte C, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Nemmen R, Nuss E, Ohsugi T, Okumura A, Orienti M, Orlando E, Ormes JF, Paneque D, Panetta JH, Perkins JS, Pesce-Rollins M, Piron F, Pivato G, Porter TA, Rainò S, Rando R, Razzano M, Razzaque S, Reimer A, Reimer O, Ritz S, Roth M, Schaal M, Schulz A, Sgrò C, Siskind EJ, Spandre G, Spinelli P, Strong AW, Takahashi H, Takeuchi Y, Thayer JG, Thayer JB, Thompson DJ, Tibaldo L, Tinivella M, Torres DF, Tosti G, Troja E, Tronconi V, Usher TL, Vandenbroucke J, Vasileiou V, Vianello G, Vitale V, Werner M, Winer BL, Wood KS, Wood M, Yang Z. Inferred cosmic-ray spectrum from Fermi large area telescope γ-ray observations of Earth's limb. PHYSICAL REVIEW LETTERS 2014; 112:151103. [PMID: 24785023 DOI: 10.1103/physrevlett.112.151103] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/13/2013] [Indexed: 06/03/2023]
Abstract
Recent accurate measurements of cosmic-ray (CR) species by ATIC-2, CREAM, and PAMELA reveal an unexpected hardening in the proton and He spectra above a few hundred GeV, a gradual softening of the spectra just below a few hundred GeV, and a harder spectrum of He compared to that of protons. These newly discovered features may offer a clue to the origin of high-energy CRs. We use the Fermi Large Area Telescope observations of the γ-ray emission from Earth's limb for an indirect measurement of the local spectrum of CR protons in the energy range ∼90 GeV-6 TeV (derived from a photon energy range 15 GeV-1 TeV). Our analysis shows that single power law and broken power law spectra fit the data equally well and yield a proton spectrum with index 2.68±0.04 and 2.61±0.08 above ∼200 GeV, respectively.
Collapse
|
112
|
Barbiellini G, Bastieri D, Bechtol K, Bellazzini R, Blandford RD, Borgland AW, Bregeon J, Bruel P, Buehler R, Buson S, Caliandro GA, Cameron RA, Caraveo PA, Cavazzuti E, Cecchi C, Chaves RCG, Chekhtman A, Cheung CC, Chiang J, Ciprini S, Claus R, Cohen-Tanugi J, D'Ammando F, de Angelis A, Dermer CD, Digel SW, do Couto E Silva E, Drell PS, Drlica-Wagner A, Favuzzi C, Focke WB, Franckowiak A, Fukazawa Y, Fusco P, Gargano F, Gasparrini D, Germani S, Giglietto N, Giommi P, Giordano F, Giroletti M, Glanzman T, Godfrey G, Grenier IA, Grove JE, Guiriec S, Hadasch D, Hayashida M, Hays E, Hughes RE, Jackson MS, Jogler T, Knödlseder J, Kuss M, Lande J, Larsson S, Longo F, Loparco F, Lovellette MN, Lubrano P, Mazziotta MN, Mehault J, Michelson PF, Mizuno T, Moiseev AA, Monte C, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Nemmen R, Nuss E, Ohsugi T, Omodei N, Orienti M, Orlando E, Paneque D, Perkins JS, Piron F, Pivato G, Prokhorov D, Rainò S, Razzano M, Razzaque S, Reimer A, Reimer O, Ritz S, Romoli C, Sánchez-Conde M, Sanchez DA, Sgrò C, Siskind EJ, Spandre G, Spinelli P, Takahashi H, Tanaka T, Tibaldo L, Tinivella M, Tosti G, Troja E, Usher TL, Vandenbroucke J, Vasileiou V, Vianello G, Vitale V, Waite AP, Winer BL, Wood KS, Yang Z. Fermi LARGE AREA TELESCOPE OBSERVATIONS OF BLAZAR 3C 279 OCCULTATIONS BY THE SUN. THE ASTROPHYSICAL JOURNAL 2014; 784:118. [PMID: 34646038 PMCID: PMC8506895 DOI: 10.1088/0004-637x/784/2/118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Observations of occultations of bright γ-ray sources by the Sun may reveal predicted pair halos around blazars and/or new physics, such as, e.g., hypothetical light dark matter particles-axions. We use Fermi Gamma-Ray Space Telescope (Fermi) data to analyze four occultations of blazar 3C 279 by the Sun on October 8 each year from 2008 to 2011. A combined analysis of the observations of these occultations allows a point-like source at the position of 3C 279 to be detected with significance of ≈3σ, but does not reveal any significant excess over the flux expected from the quiescent Sun. The likelihood ratio test rules out complete transparency of the Sun to the blazar γ-ray emission at a 3σ confidence level.
Collapse
|
113
|
Ackermann M, Ajello M, Asano K, Atwood WB, Axelsson M, Baldini L, Ballet J, Barbiellini G, Baring MG, Bastieri D, Bechtol K, Bellazzini R, Bissaldi E, Bonamente E, Bregeon J, Brigida M, Bruel P, Buehler R, Burgess JM, Buson S, Caliandro GA, Cameron RA, Caraveo PA, Cecchi C, Chaplin V, Charles E, Chekhtman A, Cheung CC, Chiang J, Chiaro G, Ciprini S, Claus R, Cleveland W, Cohen-Tanugi J, Collazzi A, Cominsky LR, Connaughton V, Conrad J, Cutini S, D’Ammando F, de Angelis A, DeKlotz M, de Palma F, Dermer CD, Desiante R, Diekmann A, Di Venere L, Drell PS, Drlica-Wagner A, Favuzzi C, Fegan SJ, Ferrara EC, Finke J, Fitzpatrick G, Focke WB, Franckowiak A, Fukazawa Y, Funk S, Fusco P, Gargano F, Gehrels N, Germani S, Gibby M, Giglietto N, Giles M, Giordano F, Giroletti M, Godfrey G, Granot J, Grenier IA, Grove JE, Gruber D, Guiriec S, Hadasch D, Hanabata Y, Harding AK, Hayashida M, Hays E, Horan D, Hughes RE, Inoue Y, Jogler T, Jóhannesson G, Johnson WN, Kawano T, Knödlseder J, Kocevski D, Kuss M, Lande J, Larsson S, Latronico L, Longo F, Loparco F, Lovellette MN, Lubrano P, Mayer M, Mazziotta MN, McEnery JE, Michelson PF, Mizuno T, Moiseev AA, Monzani ME, Moretti E, Morselli A, Moskalenko IV, Murgia S, Nemmen R, Nuss E, Ohno M, Ohsugi T, Okumura A, Omodei N, Orienti M, Paneque D, Pelassa V, Perkins JS, Pesce-Rollins M, Petrosian V, Piron F, Pivato G, Porter TA, Racusin JL, Rainò S, Rando R, Razzano M, Razzaque S, Reimer A, Reimer O, Ritz S, Roth M, Ryde F, Sartori A, Parkinson PMS, Scargle JD, Schulz A, Sgrò C, Siskind EJ, Sonbas E, Spandre G, Spinelli P, Tajima H, Takahashi H, Thayer JG, Thayer JB, Thompson DJ, Tibaldo L, Tinivella M, Torres DF, Tosti G, Troja E, Usher TL, Vandenbroucke J, Vasileiou V, Vianello G, Vitale V, Winer BL, Wood KS, Yamazaki R, Younes G, Yu HF, Zhu SJ, Bhat PN, Briggs MS, Byrne D, Foley S, Goldstein A, Jenke P, Kippen RM, Kouveliotou C, McBreen S, Meegan C, Paciesas WS, Preece R, Rau A, Tierney D, van der Horst AJ, von Kienlin A, Wilson-Hodge C, Xiong S, Cusumano G, La Parola V, Cummings JR. Fermi-LAT Observations of the Gamma-Ray Burst GRB 130427A. Science 2014; 343:42-7. [DOI: 10.1126/science.1242353] [Citation(s) in RCA: 176] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
114
|
Preece R, Burgess JM, von Kienlin A, Bhat PN, Briggs MS, Byrne D, Chaplin V, Cleveland W, Collazzi AC, Connaughton V, Diekmann A, Fitzpatrick G, Foley S, Gibby M, Giles M, Goldstein A, Greiner J, Gruber D, Jenke P, Kippen RM, Kouveliotou C, McBreen S, Meegan C, Paciesas WS, Pelassa V, Tierney D, van der Horst AJ, Wilson-Hodge C, Xiong S, Younes G, Yu HF, Ackermann M, Ajello M, Axelsson M, Baldini L, Barbiellini G, Baring MG, Bastieri D, Bellazzini R, Bissaldi E, Bonamente E, Bregeon J, Brigida M, Bruel P, Buehler R, Buson S, Caliandro GA, Cameron RA, Caraveo PA, Cecchi C, Charles E, Chekhtman A, Chiang J, Chiaro G, Ciprini S, Claus R, Cohen-Tanugi J, Cominsky LR, Conrad J, D'Ammando F, de Angelis A, de Palma F, Dermer CD, Desiante R, Digel SW, Di Venere L, Drell PS, Drlica-Wagner A, Favuzzi C, Franckowiak A, Fukazawa Y, Fusco P, Gargano F, Gehrels N, Germani S, Giglietto N, Giordano F, Giroletti M, Godfrey G, Granot J, Grenier IA, Guiriec S, Hadasch D, Hanabata Y, Harding AK, Hayashida M, Iyyani S, Jogler T, Jóhannesson G, Kawano T, Knödlseder J, Kocevski D, Kuss M, Lande J, Larsson J, Larsson S, Latronico L, Longo F, Loparco F, Lovellette MN, Lubrano P, Mayer M, Mazziotta MN, Michelson PF, Mizuno T, Monzani ME, Moretti E, Morselli A, Murgia S, Nemmen R, Nuss E, Nymark T, Ohno M, Ohsugi T, Okumura A, Omodei N, Orienti M, Paneque D, Perkins JS, Pesce-Rollins M, Piron F, Pivato G, Porter TA, Racusin JL, Rainò S, Rando R, Razzano M, Razzaque S, Reimer A, Reimer O, Ritz S, Roth M, Ryde F, Sartori A, Scargle JD, Schulz A, Sgrò C, Siskind EJ, Spandre G, Spinelli P, Suson DJ, Tajima H, Takahashi H, Thayer JG, Thayer JB, Tibaldo L, Tinivella M, Torres DF, Tosti G, Troja E, Usher TL, Vandenbroucke J, Vasileiou V, Vianello G, Vitale V, Werner M, Winer BL, Wood KS, Zhu S. The First Pulse of the Extremely Bright GRB 130427A: A Test Lab for Synchrotron Shocks. Science 2014; 343:51-4. [DOI: 10.1126/science.1242302] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
115
|
Fraioli F, Anzidei M, Serra G, Liberali S, Fiorelli A, Zaccagna F, Longo F, Anile M, Catalano C. Whole-tumour CT-perfusion of unresectable lung cancer for the monitoring of anti-angiogenetic chemotherapy effects. Br J Radiol 2013; 86:20120174. [PMID: 23908346 DOI: 10.1259/bjr.20120174] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVE To determine whether CT-perfusion (CT-p) can be used to evaluate the effects of chemotherapy and anti-angiogenic treatment in patients with non-small-cell lung carcinoma (NSCLC) and whether CT-p and standard therapeutic response assessment (RECIST) data obtained before and after therapy correlate. METHODS 55 patients with unresectable NSCLC underwent CT-p before the beginning of therapy and 50 of them repeated CT-p 90 days after it. Therapeutic protocol included platinum-based doublets plus bevacizumab for non-squamous carcinoma and platinum-based doublets for squamous carcinoma. RECIST measurements and calculations of blood flow (BF), blood volume (BV), time to peak (TTP) and permeability surface (PS) were performed, and baseline and post-treatment measurements were tested for statistically significant differences. Baseline and follow-up perfusion parameters were also compared based on histopathological subclassification (2004 World Health Organization Classification of Tumours) and therapy response assessed by RECIST. RESULTS Tumour histology was consistent with large cell carcinoma in 14/50 (28%) cases, adenocarcinoma in 22/50 (44%) cases and squamous cell carcinoma in the remaining 14/50 (28%) cases. BF and PS differences for all tumours between baseline and post-therapy measurements were significant (p=0.001); no significant changes were found for BV (p=0.3) and TTP (p=0.1). The highest increase of BV was demonstrated in adenocarcinoma (5.2±34.1%), whereas the highest increase of TTP was shown in large cell carcinoma (6.9±22.4%), and the highest decrease of PS was shown in squamous cell carcinoma (-21.5±18.5%). A significant difference between the three histological subtypes was demonstrated only for BV (p<0.007). On the basis of RECIST criteria, 8 (16%) patients were classified as partial response (PR), 2 (4%) as progressive disease (PD) and the remaining 40 (80%) as stable disease (SD). Among PR, a decrease of both BF (18±9.6%) and BV (12.6±9.2%) were observed; TTP increased in 3 (37.5%) cases, and PS decreased in 6 (75%) cases. SD patients showed an increase of BF, BV, TTP and PS in 6 (15%), 21 (52.5%), 23 (57.5%) and 2 (5%) cases, respectively. PD patients demonstrated an increase of BF (26±0.2%), BV (2.7±0.1%) and TTP (3.1±0.8%) while only PS decreased (23±0.2%). CONCLUSION CT-p can adequately evaluate therapy-induced alterations in NSCLC, and perfusion parameters correlate with therapy response assessment performed with RECIST criteria. ADVANCES IN KNOWLEDGE Evaluating perfusional parameters, CT-p can demonstrate therapy-induced changes in patients with different types of lung cancer and identify response to treatment with excellent agreement to RECIST measurements.
Collapse
|
116
|
Di Seri M, De Sanctis R, Quadrini S, Adua D, Stumbo L, Del Signore E, Gori B, Grassi P, Basile M, Longo F. Safety and Efficacy of Oral Vinorelbine and Capecitabine Combination for Metastatic Breast Cancer. J Chemother 2013; 23:110-3. [DOI: 10.1179/joc.2011.23.2.110] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
117
|
Gazzaniga P, Raimondi C, Gradilone A, Biondi Zoccai G, Nicolazzo C, Gandini O, Longo F, Tomao S, Lo Russo G, Seminara P, Vincenzi B, Chimenti I, Cristofanilli M, Frati L, Cortesi E. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff? J Cancer Res Clin Oncol 2013; 139:1411-6. [PMID: 23736274 DOI: 10.1007/s00432-013-1450-0] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2013] [Accepted: 05/17/2013] [Indexed: 02/05/2023]
Abstract
PURPOSE To assess the prognostic and predictive value of circulating tumor cells (CTCs) in metastatic colorectal cancer (mCRC) irrespective of detection level. MATERIALS AND METHODS We evaluated the prognostic and predictive significance of CTC count at baseline and under treatment in 119 mCRC subjects and compared the standard cutoff (≥3 CTCs/7.5 mL to ≥1 CTCs/7.5 mL). RESULTS An overall comparison was made between patients with 0, 1-2 and ≥3 CTC (median PFS 8, 4 and 5 months, respectively). Two poor prognostic groups were found, including patients with ≥1 CTCs before and during treatment and patients with 0 CTC at baseline who converted to ≥1 CTCs (p = 0.014). CONCLUSIONS The presence of at least 1 CTC at baseline count is predictive for poor prognosis in mCRC patients. Patients with 1-2 CTC should be switched from the favorable prognostic group--conventionally defined by the presence of <3 CTC--to the unfavorable, deserving a more careful monitoring.
Collapse
|
118
|
Caroli M, Mele RM, Tomaselli MA, Cammisa M, Longo F, Attolini E. Response to Mrs. Rapley's comments. Nutr Metab Cardiovasc Dis 2013; 23:e22. [PMID: 23557876 DOI: 10.1016/j.numecd.2012.12.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2012] [Accepted: 12/13/2012] [Indexed: 12/01/2022]
|
119
|
Olmedo E, Earl J, Guerrero C, Longo F, Alcalde R, Soria A, Grande E, Plana N, Carrato A, Garrido P. 41P IS THERE ANY ROLE FOR CIRCULATING TUMOR CELLS IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)? Lung Cancer 2013. [DOI: 10.1016/s0169-5002(13)70262-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
120
|
Gamucci T, Vaccaro A, Ciancola F, Pizzuti L, Sperduti I, Moscetti L, Longo F, Fabbri MA, Giampaolo MA, Mentuccia L, Di Lauro L, Vici P. Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis. J Cancer Res Clin Oncol 2013; 139:853-60. [PMID: 23411686 PMCID: PMC3625404 DOI: 10.1007/s00432-013-1388-2] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2012] [Accepted: 01/29/2013] [Indexed: 01/03/2023]
Abstract
PURPOSE Recurrences and deaths are known to occur, even if less frequently, in small, node-negative breast cancer patients, and decision on adjuvant treatments remains controversial. In the present analysis, we evaluate recurrence risk in patients with pT1 a, b, c, node-negative, breast cancer, accordingly with some prognostic biological factors. METHODS We retrospectively evaluated 900 node-negative patients (pT1a, b, c) surgery treated between 2000 and 2009 in four Italian oncologic centers. We defined 3 different cohorts: ER positive (ER+); Her-2 positive (Her-2+); and triple negative (TN). RESULTS pT1a was seen in 7.6% of patients, 37.7 % pT1b, 54.8 % pT1c. Concerning the 3 different cohorts, 58.2 % were ER+; 10.8 % were Her-2+; 8.2 % were TN. Overall, chemotherapy was given to 3.0 %, 27.2 %, 69.8 % of pT1a, b, c, respectively, and to 22.7 %, 58.8 %, 68.9 % of ER+, Her-2+, TN subgroups. At a median follow-up of 67 months, 5-year DFS was 96.3 %, 89.2 %, 89.4 % in pT1a, b, c, respectively (100 %, 93.6 %, 89.8 % in ER+; 100 %, 78.7 %, 85.0 % in Her-2+; 100 %, 76.8 %, 85.2 % in TN) (p = ns). At multivariate analysis, histologic grade and Ki-67 resulted independent prognostic factors. Overall, 5-year OS was 98 %, without differences among pT1a, b, c, or among the 3 cohorts. CONCLUSIONS Overall, 5-year DFS was very favorable in this series of small, node-negative breast cancers, but Her-2+ and TN cohorts have a higher recurrence rate than ER+ cohort (p < 0.0001); pT1c, but also pT1b, in Her-2+ and TN subgroups, have a worse outcome, and effective chemotherapy treatment should be considered in these unfavorable subgroups.
Collapse
|
121
|
Ackermann M, Ajello M, Allafort A, Baldini L, Ballet J, Barbiellini G, Baring MG, Bastieri D, Bechtol K, Bellazzini R, Blandford RD, Bloom ED, Bonamente E, Borgland AW, Bottacini E, Brandt TJ, Bregeon J, Brigida M, Bruel P, Buehler R, Busetto G, Buson S, Caliandro GA, Cameron RA, Caraveo PA, Casandjian JM, Cecchi C, Celik O, Charles E, Chaty S, Chaves RCG, Chekhtman A, Cheung CC, Chiang J, Chiaro G, Cillis AN, Ciprini S, Claus R, Cohen-Tanugi J, Cominsky LR, Conrad J, Corbel S, Cutini S, D'Ammando F, de Angelis A, de Palma F, Dermer CD, do Couto e Silva E, Drell PS, Drlica-Wagner A, Falletti L, Favuzzi C, Ferrara EC, Franckowiak A, Fukazawa Y, Funk S, Fusco P, Gargano F, Germani S, Giglietto N, Giommi P, Giordano F, Giroletti M, Glanzman T, Godfrey G, Grenier IA, Grondin MH, Grove JE, Guiriec S, Hadasch D, Hanabata Y, Harding AK, Hayashida M, Hayashi K, Hays E, Hewitt JW, Hill AB, Hughes RE, Jackson MS, Jogler T, Johannesson G, Johnson AS, Kamae T, Kataoka J, Katsuta J, Knodlseder J, Kuss M, Lande J, Larsson S, Latronico L, Lemoine-Goumard M, Longo F, Loparco F, Lovellette MN, Lubrano P, Madejski GM, Massaro F, Mayer M, Mazziotta MN, McEnery JE, Mehault J, Michelson PF, Mignani RP, Mitthumsiri W, Mizuno T, Moiseev AA, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Nakamori T, Nemmen R, Nuss E, Ohno M, Ohsugi T, Omodei N, Orienti M, Orlando E, Ormes JF, Paneque D, Perkins JS, Pesce-Rollins M, Piron F, Pivato G, Raino S, Rando R, Razzano M, Razzaque S, Reimer A, Reimer O, Ritz S, Romoli C, Sanchez-Conde M, Schulz A, Sgro C, Simeon PE, Siskind EJ, Smith DA, Spandre G, Spinelli P, Stecker FW, Strong AW, Suson DJ, Tajima H, Takahashi H, Takahashi T, Tanaka T, Thayer JG, Thayer JB, Thompson DJ, Thorsett SE, Tibaldo L, Tibolla O, Tinivella M, Troja E, Uchiyama Y, Usher TL, Vandenbroucke J, Vasileiou V, Vianello G, Vitale V, Waite AP, Werner M, Winer BL, Wood KS, Wood M, Yamazaki R, Yang Z, Zimmer S. Detection of the Characteristic Pion-Decay Signature in Supernova Remnants. Science 2013; 339:807-11. [DOI: 10.1126/science.1231160] [Citation(s) in RCA: 508] [Impact Index Per Article: 46.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
122
|
Pletsch HJ, Guillemot L, Fehrmann H, Allen B, Kramer M, Aulbert C, Ackermann M, Ajello M, de Angelis A, Atwood WB, Baldini L, Ballet J, Barbiellini G, Bastieri D, Bechtol K, Bellazzini R, Borgland AW, Bottacini E, Brandt TJ, Bregeon J, Brigida M, Bruel P, Buehler R, Buson S, Caliandro GA, Cameron RA, Caraveo PA, Casandjian JM, Cecchi C, Çelik Ö, Charles E, Chaves RCG, Cheung CC, Chiang J, Ciprini S, Claus R, Cohen-Tanugi J, Conrad J, Cutini S, D’Ammando F, Dermer CD, Digel SW, Drell PS, Drlica-Wagner A, Dubois R, Dumora D, Favuzzi C, Ferrara EC, Franckowiak A, Fukazawa Y, Fusco P, Gargano F, Gehrels N, Germani S, Giglietto N, Giordano F, Giroletti M, Godfrey G, Grenier IA, Grondin MH, Grove JE, Guiriec S, Hadasch D, Hanabata Y, Harding AK, den Hartog PR, Hayashida M, Hays E, Hill AB, Hou X, Hughes RE, Jóhannesson G, Jackson MS, Jogler T, Johnson AS, Johnson WN, Kataoka J, Kerr M, Knödlseder J, Kuss M, Lande J, Larsson S, Latronico L, Lemoine-Goumard M, Longo F, Loparco F, Lovellette MN, Lubrano P, Massaro F, Mayer M, Mazziotta MN, McEnery JE, Mehault J, Michelson PF, Mitthumsiri W, Mizuno T, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Nakamori T, Nemmen R, Nuss E, Ohno M, Ohsugi T, Omodei N, Orienti M, Orlando E, de Palma F, Paneque D, Perkins JS, Piron F, Pivato G, Porter TA, Rainò S, Rando R, Ray PS, Razzano M, Reimer A, Reimer O, Reposeur T, Ritz S, Romani RW, Romoli C, Sanchez DA, Parkinson PMS, Schulz A, Sgrò C, do Couto e Silva E, Siskind EJ, Smith DA, Spandre G, Spinelli P, Suson DJ, Takahashi H, Tanaka T, Thayer JB, Thayer JG, Thompson DJ, Tibaldo L, Tinivella M, Troja E, Usher TL, Vandenbroucke J, Vasileiou V, Vianello G, Vitale V, Waite AP, Winer BL, Wood KS, Wood M, Yang Z, Zimmer S. Binary Millisecond Pulsar Discovery via Gamma-Ray Pulsations. Science 2012; 338:1314-7. [PMID: 23112297 DOI: 10.1126/science.1229054] [Citation(s) in RCA: 84] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
123
|
Ackermann M, Ajello M, Allafort A, Schady P, Baldini L, Ballet J, Barbiellini G, Bastieri D, Bellazzini R, Blandford RD, Bloom ED, Borgland AW, Bottacini E, Bouvier A, Bregeon J, Brigida M, Bruel P, Buehler R, Buson S, Caliandro GA, Cameron RA, Caraveo PA, Cavazzuti E, Cecchi C, Charles E, Chaves RCG, Chekhtman A, Cheung CC, Chiang J, Chiaro G, Ciprini S, Claus R, Cohen-Tanugi J, Conrad J, Cutini S, D’Ammando F, de Palma F, Dermer CD, Digel SW, do Couto e Silva E, Domínguez A, Drell PS, Drlica-Wagner A, Favuzzi C, Fegan SJ, Focke WB, Franckowiak A, Fukazawa Y, Funk S, Fusco P, Gargano F, Gasparrini D, Gehrels N, Germani S, Giglietto N, Giordano F, Giroletti M, Glanzman T, Godfrey G, Grenier IA, Grove JE, Guiriec S, Gustafsson M, Hadasch D, Hayashida M, Hays E, Jackson MS, Jogler T, Kataoka J, Knödlseder J, Kuss M, Lande J, Larsson S, Latronico L, Longo F, Loparco F, Lovellette MN, Lubrano P, Mazziotta MN, McEnery JE, Mehault J, Michelson PF, Mizuno T, Monte C, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Tramacere A, Nuss E, Greiner J, Ohno M, Ohsugi T, Omodei N, Orienti M, Orlando E, Ormes JF, Paneque D, Perkins JS, Pesce-Rollins M, Piron F, Pivato G, Porter TA, Rainò S, Rando R, Razzano M, Razzaque S, Reimer A, Reimer O, Reyes LC, Ritz S, Rau A, Romoli C, Roth M, Sánchez-Conde M, Sanchez DA, Scargle JD, Sgrò C, Siskind EJ, Spandre G, Spinelli P, Stawarz Ł, Suson DJ, Takahashi H, Tanaka T, Thayer JG, Thompson DJ, Tibaldo L, Tinivella M, Torres DF, Tosti G, Troja E, Usher TL, Vandenbroucke J, Vasileiou V, Vianello G, Vitale V, Waite AP, Winer BL, Wood KS, Wood M. The Imprint of the Extragalactic Background Light in the Gamma-Ray Spectra of Blazars. Science 2012; 338:1190-2. [DOI: 10.1126/science.1227160] [Citation(s) in RCA: 184] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
124
|
Falzarano R, Viggiani V, Michienzi S, Colaprisca B, Longo F, Frati L, Anastasi E. CLEIA CA125 evidences: good analytical performance avoiding “Hook effect”. Tumour Biol 2012; 34:387-93. [DOI: 10.1007/s13277-012-0561-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2012] [Accepted: 10/12/2012] [Indexed: 01/26/2023] Open
|
125
|
Longo F, Perri F, Aversa C, Pavone E, Caponigro F, Ionna F. Electrochemotherapy, a novel integrated approach to the locoregional treatment of head and neck cancer. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.07.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|